Bill Gates in new push against malaria

Billionaire Bill Gates and thousands of babies are helping Africa prepare its largest medical experiment ever in the search for a new vaccine against malaria.

Researchers say the push comes at a crucial time in the battle against a disease that has been beaten back several times before, only to resurge with deadly vigour.

For Dr Zena Mtajuka, an exhausted warrior on the frontlines of the fight against one of the world’s most devastating diseases, a vaccine cannot come quickly enough.

”Malaria is our number one killer in this district,” said Mtajuka in her cramped office at Bagamoyo District Hospital, north of Tanzania’s capital, Dar es Salaam.

”The hardest thing is that members of the community come to the hospital too late. It makes them harder to save.”

Bagamoyo is one of almost a dozen research sites where scientists are in the final stages of preparing for a large-scale efficacy and safety trial of the ”RTS,S” vaccine developed by GlaxoSmithKline PLC.

The trial, which is expected to begin early next year and will involve 16 000 children in seven African countries, is the largest ever undertaken on the continent. Its funders, including groups supported by the Gates Foundation, hope it will result in a new and effective strategy to fight the disease.

Bagamoyo’s malaria burden is typical of many places in tropical Africa, home to most of the almost one million people who die each year as a result of the mosquito-borne illness.

Public health officials estimate that malaria costs Africa $12-billion owing to deaths and lost productivity, a twin burden the world’s poorest continent cannot afford.

Public health advocates have cited malaria as an emerging global health success story, with new drugs, bed nets and insecticides contributing to sharp drops in infection rates in a number of countries.

Mtajuka said insecticide-treated bed nets and indoor spraying are not universally available here despite campaigns to promote them.

”Some people are using bed nets, but not all of them. Some are simply too poor to afford them. And since I’ve been here there’s been no indoor spraying. I think we had it once, three years ago, but not since then.”

Mtajuka manages the hospital’s HIV/Aids clinic, but earlier this year she had to take over as malaria officer after her predecessor died — from malaria.

Measuring success
Like many African doctors, Mtajuka is swamped with malaria cases — which proponents say underscores the need for a vaccine to stop the deadly parasite in its tracks.

”Drugs and nets are going to assist, but I don’t think that’s a long-term solution,” said Dr Norbert Peshu, director of the KEMRI Centre for Geographic Medicine Research in Kilifi, Kenya, another malaria hotspot.

”The final thing against malaria has to be a vaccine.”

The RTS,S vaccine was identified as promising two decades ago, but has only recently moved into widespread testing, thanks to funding from the PATH Malaria Vaccine Initiative supported by the Bill and Melinda Gates Foundation.

For vaccinologists, malaria has proved hard to beat. The parasite that causes the disease has a complex life-cycle inside mosquitoes and the human body that helps it evade the immune system.

RTS,S, named for the antigen it produces, fuses part of a protein from the parasite to the surface of a hepatitis-B viral particle, stimulating the body’s immune response. This hobbles the parasite’s ability to infect and develop in the liver, its main repository in humans, which gives partial protection against the disease.

The vaccine’s largest test so far, in more than 2 000 children in Mozambique starting in 2003, showed it reduced all cases of clinical malaria by 35% and the worst cases of the disease by about 50%.

The Malaria Vaccine Initiative, which helps coordinate world malaria vaccine research and development, aims for a vaccine that is at least 50% effective by 2015 and a second-generation product to confer 80% or more protection against clinical disease by 2025.

”It may not cover all the bases, but it could cover some of them,” said Dr Patricia Njuguna, a Kenyan paediatrician who will be one of the principal investigators for the next series of RTS,S human trials.

”Traditional vaccines give 80 to 90% protection. Malaria vaccines give less. But perhaps that is all you need.”

No single answer
Many medical workers in Africa say that while even a partially effective malaria vaccine would be welcome, it would not be the answer to the continent’s health problems.

Stephen Chakaya, a 27-year-old medical officer at a rural clinic in Junju outside Kilifi, Kenya, said poverty and hunger were just as destructive as malaria in the community and much harder to address.

”Most of the people around here live on less than $1 per day,” Chakaya noted, standing in his basic clinic that serves nearly 6 000 people in the area.

”We don’t have a lab here. We don’t have a microscope. We don’t have slides, so we can never be sure if a case is malaria or something else. We need investment,” he said.

But researchers say the vaccine push is bringing this investment, helping to supply equipment and expertise that will eventually benefit the community at large.

In Bagamoyo, where the vaccine trials are being run by Tanzania’s Ifakara Health Institute with the district hospital, vaccine money has helped to purchase new ambulances and equip a new paediatric ward that takes care of all children under five who are admitted to the hospital.

Major investment in bed nets and combination therapies with artimisinin-based drugs have added pressure on the parasite, which appeared to be on the retreat in some areas of Africa.

Wendy O’Meara, a United tates. epidemiologist working at the KEMRI/Wellcome Centre in Kilifi, said reviews of local hospital data showed the mean age of children admitted with malaria had been rising over the past 10 years, a signal that the parasite was becoming rarer.

She said the changes came before bed nets and combination drug therapies were widely available in Kilifi, indicating other factors were responsible.

”There are very few places on the planet where malaria runs its natural course,” she said. ”It could be economic development, it could be things we don’t have data on, or aren’t creative enough to think of yet.” (c) Reuters 2008.

An actual Black Friday deal

Subscribe for R2/mth for the first three months. Cancel anytime.

Subscribers get access to all our best journalism, subscriber-only newsletters, events and a weekly cryptic crossword.

Related stories

WELCOME TO YOUR M&G

Already a subscriber? Sign in here

Advertising

Latest stories

Magashule wants court to throw out state’s case against him

Former Free State premier asks the court to declare that the state's case against him contains no evidence that would lead to a successful conviction

Brakes put on foreign truck drivers

New legislation aims to protect local jobs in the transport sector amid questions as to whether SA has enough willing and skilled drivers

Western Cape schools benefit from zero waste project

The initiative provides schools with a toolkit to reduce the waste they send to landfills by recycling more effectively

The Mozambican criminal who escaped from South African prisons, twice

A rhino-poaching suspect, who recently escaped from police custody, has been identified as a criminal who was serving multiple life sentences when he broke out of prison last year
Advertising

press releases

Loading latest Press Releases…
×